Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Neuronetics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Neuronetics's regulatory disclosures and financial reporting.
Sullivan Keith J reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. reported that President and CEO Keith J. Sullivan received a grant of 112,500 shares of common stock. The shares were issued for no cash consideration upon satisfaction of performance criteria tied to performance-based restricted stock units. Following this award, Sullivan directly holds 1,637,213 shares of Neuronetics common stock. This is a compensation-related equity award rather than an open-market purchase.
Neuronetics, Inc. reported that its EVP, CLO and CS, William Andrew Macan, received an award of 33,750 shares of common stock. These shares were granted for no cash consideration after performance criteria tied to performance-based restricted stock units were satisfied. Following this equity award, his directly held common stock position increased to 913,275 shares, highlighting a compensation-related, non-market acquisition rather than an open-market purchase.
Pfanstiel Steven reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. reported that EVP, CFO and Treasurer Steven Pfanstiel received an equity grant of 25,000 restricted stock units (RSUs). Each RSU represents a right to receive one share of common stock, vesting in three equal annual installments beginning on March 17, 2027, subject to his continuous service. Following this award, Pfanstiel is shown as holding 845,212 shares of common stock directly.
Neuronetics, Inc. major shareholder Jorey Chernett reported an open-market purchase of 531,000 shares of common stock at a weighted average price of $1.16 per share. The filing notes the shares were bought in multiple trades between $0.91 and $1.31 per share. Following this transaction, Chernett directly owns 7,516,404 shares of Neuronetics common stock.
Neuronetics, Inc. reported that significant shareholder Jorey Chernett beneficially owns 6,985,404 shares of the company’s common stock. This Form 3 filing is an initial statement of holdings by a more than ten percent owner and does not reflect any new share transactions.
Neuronetics, Inc. filing amends beneficial ownership disclosure for Jorey Chernett. As of the close of business on March 17, 2026, the Reporting Person beneficially owned 7,516,404 shares of Common Stock, representing 10.85% of the class based on 69,276,593 Shares outstanding as of March 10, 2026.
The amendment updates the Schedule 13G/A ownership figures and reports sole voting and dispositive power over the disclosed shares. The statement is signed and dated 03/18/2026.
Neuronetics, Inc. registers up to 20,737,061 shares of its common stock for resale by selling stockholders pursuant to a shelf prospectus dated March 17, 2026.
The prospectus states the Company will receive no proceeds from these sales and identifies Madryn-related entities as the primary selling stockholders, who beneficially owned a combined portion of outstanding shares as of March 10, 2026. The filing describes distribution methods, indemnities, and that the shares represent a significant percentage of outstanding common stock, which could affect market price if sold concurrently.
Neuronetics, Inc. ownership filing: Parian Ultreia reports beneficial ownership of 4,844,908 shares, equal to 7.0% of the class, with sole voting and dispositive power over those shares. The filing is signed by Portfolio Manager Zachary Miller on 03/17/2026.
Neuronetics, Inc. reports strong 2025 growth while remaining unprofitable as it integrates Greenbrook TMS. Revenue reached $149.2 million for the year ended December 31, 2025, up 99% from 2024, driven largely by its NeuroStar TMS platform and newly acquired Greenbrook treatment centers.
U.S. revenue was $146.0 million, up 101% year over year. Clinic revenue rose to 59% of U.S. revenue from 6% as Neuronetics shifted toward operating 93 Greenbrook treatment centers, while treatment-session revenue fell to 30% from 70%. The company still posted a net loss of $39.1 million and has an accumulated deficit of $458.8 million, highlighting ongoing profitability and integration challenges despite rapid top-line expansion.
Neuronetics, Inc. reported strong growth for Q4 and full-year 2025 alongside a leadership change. Q4 2025 revenue was $41.8 million, up 86% from Q4 2024, driven mainly by the Greenbrook clinic acquisition. Full-year 2025 revenue nearly doubled to $149.2 million from $74.9 million, with U.S. revenue up 101%.
Profitability remains a challenge: full-year gross margin fell to 48.5% from 72.3%, and net loss was $(39.1) million, an improvement from $(43.7) million. The company ended 2025 with $34.1 million in cash and restricted cash and generated $0.9 million of operating cash in Q4.
The board appointed Dan Reuvers as President and CEO effective March 23, 2026, with an initial base salary of $730,000 and a grant of 1.5 million RSUs. For 2026, Neuronetics guides to revenue of $160–$166 million, expects operating expenses of $100–$105 million, and anticipates significantly improved operating cash flow as efficiency initiatives and the Greenbrook integration progress.